Vaxart, Inc. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Vaxart, Inc. (VXRT) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$4.09 million for the 3-month period ending 2012-09-30, per its 10-Q filed 2012-11-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2012-11-08
- Vaxart, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2012-09-30 was -$4.09M.
- Vaxart, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2012-06-30 was -$2.73M.
- Vaxart, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2012-03-31 was -$1.43M, a 172.07% decline year-over-year.
- Vaxart, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2011-12-31 was -$1.99M.
- Vaxart, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2011 was -$7.51M, a 955.69% decline from fiscal 2010.
- Vaxart, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2010 was $878.00K.
- Vaxart, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2009 was -$18.73M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2012-09-30 | -$4.09M 10-Q · filed 2012-11-08 | -$6.82M derived: sum of 2 quarters · filed 2012-11-08 | -$8.25M 10-Q · filed 2012-11-08 | -$10.24M derived: sum of 4 quarters · filed 2012-11-08 |
| 2012-06-30 | -$2.73M 10-Q · filed 2012-08-09 | -$4.16M 10-Q · filed 2012-08-09 | -$6.15M derived: sum of 3 quarters · filed 2012-08-09 | -$9.05M derived: sum of 4 quarters · filed 2012-08-09 |
| 2012-03-31 | -$1.43M 10-Q · filed 2012-05-10 | -$3.42M derived: sum of 2 quarters · filed 2012-05-10 | -$6.32M derived: sum of 3 quarters · filed 2012-05-10 | -$10.92M derived: sum of 4 quarters · filed 2012-08-09 |
| 2011-12-31 | -$1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-14 | -$4.89M derived: sum of 2 quarters · filed 2012-03-14 | -$9.49M derived: sum of 3 quarters · filed 2012-08-09 | -$7.51M 10-K · filed 2012-03-14 |
| 2011-09-24 | -$2.90M 10-Q · filed 2012-11-08 | -$7.50M derived: sum of 2 quarters · filed 2012-08-09 | -$5.52M 10-Q · filed 2012-11-08 | -$11.85M derived: sum of 4 quarters · filed 2012-08-09 |
| 2011-06-25 | -$4.60M 10-Q · filed 2012-08-09 | -$2.62M 10-Q · filed 2012-08-09 | -$8.95M derived: sum of 3 quarters · filed 2012-08-09 | -$3.81M derived: sum of 4 quarters · filed 2012-08-09 |
| 2011-03-26 | $1.98M 10-Q · filed 2012-05-10 | -$4.35M derived: sum of 2 quarters · filed 2012-05-10 | $784.00K derived: sum of 3 quarters · filed 2012-05-10 | |
| 2010-12-25 | -$6.33M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-14 | -$1.20M derived: sum of 2 quarters · filed 2012-03-14 | $878.00K 10-K · filed 2012-03-14 | |
| 2010-09-25 | $5.13M 10-Q · filed 2011-11-02 | $7.21M 10-Q · filed 2011-11-02 | ||
| 2009-12-26 | -$18.73M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |